Antibody · 림프종 · FRα

9개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved9 programs
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
AntibodyLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#LargeB-cellLymphoma+2
Trials 29Status Recruiting
AntibodyLimited DatastaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#monoclonal-antibody#Relapsed+2
Trials 6Status Discontinued
AntibodyLimited DatastaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 4Status Active
AntibodyLimited DatastalePETHEMA FoundationPhase 2

ibritumomab tiuxetan (ibritumomab tiuxetan)

Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 2Status Discontinued
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryPeripheralTC+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Orelabrutinib and Rituximab (Orelabrutinib and Rituximab)

Follicular Lymphoma; Relapsed and Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#FollicularLymphoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active